About durvalumab
PD-L1 immune checkpoint inhibitor
Used for
- Certain lung cancers, including non-small cell and small cell lung cancer
- Unresectable biliary tract cancer with chemotherapy
- Unresectable hepatocellular carcinoma with tremelimumab
Usual adult dose
Usually 1,500 mg intravenously every 3 or 4 weeks; dosing varies by cancer and body weight.
Common side effects
- Fatigue, cough, and nausea
- Rash or itching
- Diarrhea or abdominal pain
- Immune-related inflammation of organs, including lungs, liver, or thyroid
Important warnings
- Can cause serious immune reactions affecting any organ, sometimes after treatment ends.
- Seek urgent care for breathing difficulty, severe diarrhea, jaundice, or confusion.
- Infusion reactions can occur.
- Treatment may require monitoring and corticosteroids for immune complications.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for 3 months after the last dose.
Breastfeeding
Avoid breastfeeding during treatment and for 3 months after the last dose.
Interactions
- Other immune-activating medicines may increase immune-related side effects.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.